ZLDAF (Zelira Therapeutics) FCF Margin %: 0.00% (As of Jun. 2025)

What is Zelira Therapeutics FCF Margin %?

Zelira Therapeutics ZLDAF 10 FCF Margin % is 0.00% as of Jun. 2025. GuruFocus rates ZLDAF with a GF Score™ of 10/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 957 Biotechnology companies, Zelira Therapeutics ranks worse than 99.16% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Zelira Therapeutics's Free Cash Flow for the six months ended in Jun. 2025 was $-1.48 Mil. Zelira Therapeutics's Revenue for the six months ended in Jun. 2025 was $0.00 Mil. Therefore, Zelira Therapeutics's FCF Margin % for the quarter that ended in Jun. 2025 was 0.00%.

As of today, Zelira Therapeutics's current FCF Yield % is -82.48%.

The historical rank and industry rank for Zelira Therapeutics's FCF Margin % or its related term are showing as below:

ZLDAF' s FCF Margin % Range Over the Past 10 Years
Min: -490700 Med: -2408.31 Max: -611.75
Current: -314800

During the past 13 years, the highest FCF Margin % of Zelira Therapeutics was -611.75%. The lowest was -490700.00%. And the median was -2408.31%.

ZLDAF's FCF Margin % is ranked worse than
99.16% of 957 companies
in the Biotechnology industry
Industry Median: -84.65 vs ZLDAF: -314800.00

Zelira Therapeutics FCF Margin % Related Terms

Zelira Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics FCF Margin % Chart

Zelira Therapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

FCF Margin %

Get a 7-Day Free Trial

-1,990.33

-611.73

-2,408.42

-4,625.40

-319,500.00

Zelira Therapeutics Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
FCF Margin %	Get a 7-Day Free Trial															-1,630.67	-3,132.43	-6,533.33	-166,700.00	0.00

ZLDAF vs MTNB, SXTP, GLMD: FCF Margin % Comparison

For the Biotechnology subindustry, Zelira Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's FCF Margin % falls into.

Save Embed

10GF Score

Zelira Therapeutics Ltd ZLDAF

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Zelira Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Zelira Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2025 )	/	Revenue (A: Jun. 2025 )
	=	-3.195	/	0.001
	=	-319,500.00 %

Zelira Therapeutics's FCF Margin for the quarter that ended in Jun. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2025 )	/	Revenue (Q: Jun. 2025 )
	=	-1.481	/	0
	=	%

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of 0.00% mean?

Zelira Therapeutics (ZLDAF) has a FCF Margin % of 0.00% as of Jun. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zelira Therapeutics and its competitors. According to the industry distribution chart, Zelira Therapeutics ranks #949 out of 957 companies in the Biotechnology industry, placing it in the top 99.2%.

Is Zelira Therapeutics' FCF Margin % too high?

Zelira Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Zelira Therapeutics ranks #949 out of 957 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zelira Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Zelira Therapeutics' FCF Margin % compare to MTNB and SXTP?

According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #949 out of 957 companies for FCF Margin %. This places Zelira Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Zelira Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Zelira Therapeutics (ZLDAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.35 — trading 337.5% above its estimated fair value. The current FCF Margin % is 0.00%. Zelira Therapeutics' overall GF Score™ is 10/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current FCF Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of $0.35 is trading 337.5% above its estimated GF Value™ of $0.08. GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.

Key valuation signals for ZLDAF:

FCF Margin %: 0.00%
GF Value™: $0.08 vs. price of $0.35 (337.5% above fair value)
GF Score™: 10/100 with 7 warning signs

No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zelira Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies MTNB SXTP GLMD FBLG ARTL CELZ REVB ALZN RNAZ ENSC VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000

Website https://www.zeliratx.com

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.

10GF Score

Get the complete analysis for ZLDAF

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35

Price

$0.08

GF Value

View ZLDAF Analysis

See FCF Margin % data for all stocks →